Popular Ice Cream Brand Faces Urgent Recall After Contamination Scare
Ice cream lovers, beware. Your favorite brand may be affected by a recent FDA recall.
Wells Enterprises, an Iowa-based company, has voluntarily recalled nearly 18,000 containers of ice cream and frozen yogurt due to the potential presence of plastic contamination.
The manufacturer is known for popular brands like Halo Top and Blue Bunny.
The recall affects 22 flavors of ice cream and frozen yogurt packaged in 3-gallon tubs, distributed to 103 locations across the U.S. This includes centers in Le Mars, Iowa; Wyoming; Michigan; Rosemont, Illinois; and both Houston and Fort Worth, Texas.
Some of the ice cream was distributed to food service suppliers and restaurants, including Gordon Food Service, US Foods, and Sysco Corp, as well as Johnny Rockets and Planet Smoothie locations.
The affected products have "Best If Used By" dates ranging from March 2026 to October 2026.
The FDA has classified the recall as a Class II event, meaning the affected products may cause "temporary or medically reversible adverse health consequences" if consumed.
So far, there have been no reported illnesses in relation to the recall.
Since the ice cream was distributed in bulk, it's unlikely to be sitting in a typical home freezer. However, if you run a business, shop at bulk food stores, or are a customer of any of the affected brands, it's important to be aware of the recall.
Wells Enterprises has not released a statement regarding the recall. But, as with any recall, the standard guidance is to either dispose of the affected product or return it to the place of purchase for a refund.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
VR Headset offers new way for Des Moines lifeguards to train
DES MOINES, Iowa — Des Moines Parks and Recreation has a VR headset that lifeguards at its public pools are now using to train. Ian Knutsen, a Recreation Superintendent with Des Moines Parks and Recreation, said that the VR headset allows lifeguards to simulate real-life emergencies. 'Our VR headset is a really new tool that we've been utilizing. It uses virtual reality that shows actual like real-life scenarios at different areas. So water parks, lap lanes, and it shows a swimmer in distress. So that way our guards can see and react to what would be an act of drowning,' Knutsen said. Four-day school week 'went fantastic' says Saydel Superintendent The VR headset uses a program developed by the Red Cross to help develop the scanning skill, which involves watching the pool for swimmers exhibiting the signs of drowning. Nick Shelton, a Recreation Supervisor with Des Moines Parks and Recreation, said that scanning is the most important skill lifeguards can have. 'That's the most important skill for a lifeguard because we really want to focus on preventative lifeguarding, not, you know, reactive lifeguard. We want to get there before the actual drowning happens, not after,' Shelton said. Des Moines Parks and Recreation will open Ashworth, Nahas, Northwest, and Teachout Aquatic Center this Saturday, June 7th. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
M-novator Demo Day Ignites Medical Innovation, Shaping the Future of MedTech
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@ Website: View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr. Yuxuan Wu, Co-founder and CEO of YolTech Therapeutics. "In vivo gene editing represents a new generation of therapeutics—offering one-time, durable solutions for chronic and genetic diseases. We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases. '' About YOLT-101 YOLT-101 is an investigational in vivo base editing therapy designed to be a single-dose treatment to durably reduce blood LDL-C. It is based on YolTech's proprietary adenine base editor, YolBE—specifically hpABE5—which comprises nCas and a novel deaminase evolved from Hafnia paralvei. For delivery, YOLT-101 utilizes YolTech's innovative lipid nanoparticle (LNP) delivery system. Unlike traditional CRISPR/Cas9 systems that rely on DNA double-strand breaks (DSBs), hpABE5 enables precise A•T to G•C base conversion without introducing DSBs, thereby significantly reducing risks of chromosomal abnormalities and off-target effects. YOLT-101 is being evaluated in ongoing investigator-initiated trial (IIT), where it has demonstrated a favorable safety profile and robust LDL-C–lowering effects. For detailed clinical data, please refer to: About Familial Hypercholesterolemia (FH) Familial hypercholesterolemia (FH) is caused by mutations in LDL metabolism-related genes such as LDLR, APOB, and PCSK9. Patients with FH exhibit significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of early-onset atherosclerotic cardiovascular disease (ASCVD). The estimated global prevalence of FH is 1 in 200 to 1 in 250, affecting approximately 34 million individuals worldwide. Current treatment strategies—lifestyle modifications, statins, ezetimibe, PCSK9 inhibitors, lipoprotein apheresis, and even liver transplantation—often fall short in terms of efficacy, tolerability, or patient adherence. This creates a critical unmet need for durable, one-time therapies that can address the root cause of disease. About YolTech YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing. To learn more, please visit: View original content: SOURCE YolTech Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data